Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045, India
The global acute migraine treatment market size is projected to be valued at US$ 8.6 Billion in 2032 and exhibit a CAGR of 4.9% in the forecast period from 2022 to 2032. It is anticipated to reach US$ 2.4 Billion in 2022. The rising prevalence of migraine owing to the rapid adoption of unhealthy lifestyles is anticipated to boost the demand for acute migraine treatment options in the near future.
Report Attribute | Details |
---|---|
Acute Migraine Treatment Market Estimated Base Year Value (2021) | US$ 1.8 Billion |
Acute Migraine Treatment Market Expected Market Value (2022) | US$ 2.4 Billion |
Acute Migraine Treatment Market Anticipated Forecast Value (2032) | US$ 8.6 Billion |
Acute Migraine Treatment Market Projected Growth Rate (2022 to 2032) | 4.9% CAGR |
Migraine is considered to be a primary headache disorder that is often characterized by recurrent attacks. Ergot alkaloids, nonsteroidal anti-inflammatory drugs, combination analgesics, triptans, and acetaminophen are some of the commonly used drugs for the treatment of migraine.
The treatment of acute migraine is a challenging task owing to the difficulty in predicting individual response to a specific dose or substantial rates of nonresponse to medicines. After the onset of symptoms, abortive therapy is mainly used as soon as possible for treating the condition.
Opioids are usually prescribed for acute migraines in the Emergency Department (ED) despite published guidelines suggesting non-opioid treatments for the same. In addition to that, subcutaneous sumatriptan, prochlorperazine, and intravenous metoclopramide are given to adults suffering from acute migraine.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The surging demand for high-quality drugs and increasing awareness among people regarding the treatment and prevention of migraine are projected to bolster the sales of acute migraine treatment options. The rising consumption of alcohol, increasing smoking habits, and surging work pressure are some of the other factors that are anticipated to augur well for the global market.
As per the 2019 National Survey on Drug Use and Health (NSDUH), around 85.6% of people between the age group of 18 years and above reported that they drank alcohol at some point in their life, while nearly 69.5% mentioned that they consumed alcohol in the past year. These numbers are expected to grow at a fast pace in the upcoming years, thereby driving growth in this market.
As the majority of the drugs are still under development, only a handful of them is available for consumption. Various side effects associated with the available drugs, such as dizziness, shortness of breath, nausea, and chest pressure may hinder the global acute migraine treatment market growth in future years.
North America is projected to lead in terms of the acute migraine treatment market share in the evaluation period. The rising investment by key players based in the USA and Canada in exhaustive research and development activities to find out new treatment options is estimated to bode well for the regional market.
According to the American Family Physician, nearly 44.5 million adults, including 6% to 9% of men and 18% to 26% of women in the USA suffered from a migraine in 2009. The annual direct costs for migraine surpass US$ 17 billion in the country. This trend is projected to continue throughout the forecast period, thereby propelling the North American market.
The rising healthcare expenditure and the ongoing development of the healthcare infrastructure in emerging countries, such as China and India are anticipated to spur the Asia Pacific acute migraine treatment market size. The easy availability of cost-effective treatment options for migraine backed by rising initiatives by regulatory bodies is another vital factor that is likely to accelerate the regional market.
As per the India Brand Equity Foundation (IBEF), the Indian healthcare infrastructure is estimated to be valued at US$ 349.1 billion by FY22. The penetration of health insurance is likely to expand in this country owing to the increasing demand for quality and affordable healthcare. This factor is set to boost growth across the Asia Pacific.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the prominent companies present in the global acute migraine treatment market are Teva Pharmaceutical, Hoffmann-La Roche Ltd., Johnson and Johnson, Amgen, AstraZeneca, Pfizer Inc., Merck & Co., Novartis AG, and Eli Lilly and Company among others.
Leading vendors operating in the global market are increasingly focusing on broadening their geographic footprint across emerging regions, such as the Middle East, Asia Pacific, and Latin America. Meanwhile, a few other key players are engaging in mergers and acquisitions with start-up companies to strengthen their positions in the global market.
Report Attribute | Details |
---|---|
Growth Rate | CAGR of 4.9% from 2022 to 2032 |
Base Year for Estimation | 2021 |
Historical Data | 2015 to 2020 |
Forecast Period | 2022 to 2032 |
Quantitative Units | Revenue in USD Billion, Volume in Kilotons, and CAGR from 2022 to 2032 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
1. Executive Summary | Acute Migraine Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. Value Chain Analysis 3.5.1. Profit Margin Analysis 3.5.2. Service Providers 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2022 to 2032 5.3.1. Analgesics 5.3.2. Ergot Alkaloids (Dihydroergotamine) 5.3.3. Triptans 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Drug Type, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032 6.3.1. Oral 6.3.2. Intranasal 6.3.3. Intramuscular 6.3.4. Intravenous 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Specialty Pharmacies 7.3.4. Mail Order Pharmacy 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Mexico 10.2.1.2. Brazil 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. United Kingdom 11.2.1.5. Spain 11.2.1.6. BENELUX 11.2.1.7. Russia 11.2.1.8. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia and New Zealand 13.2.1.4. Rest of South Asia & Pacific 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of Middle East and Africa 14.2.2. By Drug Type 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Drug Type 15.1.2.2. By Route of Administration 15.1.2.3. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Drug Type 15.2.2.2. By Route of Administration 15.2.2.3. By Distribution Channel 15.3. Mexico 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Drug Type 15.3.2.2. By Route of Administration 15.3.2.3. By Distribution Channel 15.4. Brazil 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Drug Type 15.4.2.2. By Route of Administration 15.4.2.3. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Drug Type 15.5.2.2. By Route of Administration 15.5.2.3. By Distribution Channel 15.6. Italy 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Drug Type 15.6.2.2. By Route of Administration 15.6.2.3. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Drug Type 15.7.2.2. By Route of Administration 15.7.2.3. By Distribution Channel 15.8. United Kingdom 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Drug Type 15.8.2.2. By Route of Administration 15.8.2.3. By Distribution Channel 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Drug Type 15.9.2.2. By Route of Administration 15.9.2.3. By Distribution Channel 15.10. BENELUX 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Drug Type 15.10.2.2. By Route of Administration 15.10.2.3. By Distribution Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Drug Type 15.11.2.2. By Route of Administration 15.11.2.3. By Distribution Channel 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Drug Type 15.12.2.2. By Route of Administration 15.12.2.3. By Distribution Channel 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Drug Type 15.13.2.2. By Route of Administration 15.13.2.3. By Distribution Channel 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Drug Type 15.14.2.2. By Route of Administration 15.14.2.3. By Distribution Channel 15.15. India 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Drug Type 15.15.2.2. By Route of Administration 15.15.2.3. By Distribution Channel 15.16. ASIAN 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Drug Type 15.16.2.2. By Route of Administration 15.16.2.3. By Distribution Channel 15.17. Australia and New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Drug Type 15.17.2.2. By Route of Administration 15.17.2.3. By Distribution Channel 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Drug Type 15.18.2.2. By Route of Administration 15.18.2.3. By Distribution Channel 15.19. Turkey 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Drug Type 15.19.2.2. By Route of Administration 15.19.2.3. By Distribution Channel 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Drug Type 15.20.2.2. By Route of Administration 15.20.2.3. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Type 16.3.3. By Route of Administration 16.3.4. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Novartis International AG 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Janssen Pharmaceuticals, Inc 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Pfizer Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Zydus Cadila 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Abbott 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Sun Pharmaceutical Industries Ltd 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Dr. Reddy's Laboratories Ltd 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Micro Labs Ltd 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Glaxo SmithKline Pharmaceuticals Ltd 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Piramal Healthcare Limited 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. Sanofi S.A. 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. Hetero Drugs Ltd 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. Lupin Ltd 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 17.1.14. Alkem Laboratories Ltd 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.14.5.2. Product Strategy 17.1.14.5.3. Channel Strategy 17.1.15. Apex Laboratories Pvt Ltd 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 17.1.15.5.2. Product Strategy 17.1.15.5.3. Channel Strategy 17.1.16. Intas Pharmaceuticals Ltd 17.1.16.1. Overview 17.1.16.2. Product Portfolio 17.1.16.3. Profitability by Market Segments 17.1.16.4. Sales Footprint 17.1.16.5. Strategy Overview 17.1.16.5.1. Marketing Strategy 17.1.16.5.2. Product Strategy 17.1.16.5.3. Channel Strategy 17.1.17. Cipla Ltd 17.1.17.1. Overview 17.1.17.2. Product Portfolio 17.1.17.3. Profitability by Market Segments 17.1.17.4. Sales Footprint 17.1.17.5. Strategy Overview 17.1.17.5.1. Marketing Strategy 17.1.17.5.2. Product Strategy 17.1.17.5.3. Channel Strategy 17.1.18. Healing Pharma 17.1.18.1. Overview 17.1.18.2. Product Portfolio 17.1.18.3. Profitability by Market Segments 17.1.18.4. Sales Footprint 17.1.18.5. Strategy Overview 17.1.18.5.1. Marketing Strategy 17.1.18.5.2. Product Strategy 17.1.18.5.3. Channel Strategy 17.1.19. Torrent Pharmaceuticals Ltd 17.1.19.1. Overview 17.1.19.2. Product Portfolio 17.1.19.3. Profitability by Market Segments 17.1.19.4. Sales Footprint 17.1.19.5. Strategy Overview 17.1.19.5.1. Marketing Strategy 17.1.19.5.2. Product Strategy 17.1.19.5.3. Channel Strategy 17.1.20. Alembic Pharmaceuticals Ltd 17.1.20.1. Overview 17.1.20.2. Product Portfolio 17.1.20.3. Profitability by Market Segments 17.1.20.4. Sales Footprint 17.1.20.5. Strategy Overview 17.1.20.5.1. Marketing Strategy 17.1.20.5.2. Product Strategy 17.1.20.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032 Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032 Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 6: North America Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 14: Europe Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032 Table 17: East Asia Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 18: East Asia Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 19: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 20: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032 Table 21: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 22: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 23: South Asia & Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 24: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032 Table 25: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 26: MEA Market Value (US$ Million) Forecast by Drug Type, 2017 to 2032 Table 27: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032 Table 28: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Figure 1: Global Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 4: Global Market Value (US$ Million) by Region, 2022 to 2032 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 8: Global Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 17: Global Market Attractiveness by Drug Type, 2022 to 2032 Figure 18: Global Market Attractiveness by Route of Administration, 2022 to 2032 Figure 19: Global Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 20: Global Market Attractiveness by Region, 2022 to 2032 Figure 21: North America Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 24: North America Market Value (US$ Million) by Country, 2022 to 2032 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 28: North America Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 37: North America Market Attractiveness by Drug Type, 2022 to 2032 Figure 38: North America Market Attractiveness by Route of Administration, 2022 to 2032 Figure 39: North America Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 40: North America Market Attractiveness by Country, 2022 to 2032 Figure 41: Latin America Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 44: Latin America Market Value (US$ Million) by Country, 2022 to 2032 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 57: Latin America Market Attractiveness by Drug Type, 2022 to 2032 Figure 58: Latin America Market Attractiveness by Route of Administration, 2022 to 2032 Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032 Figure 61: Europe Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 64: Europe Market Value (US$ Million) by Country, 2022 to 2032 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 77: Europe Market Attractiveness by Drug Type, 2022 to 2032 Figure 78: Europe Market Attractiveness by Route of Administration, 2022 to 2032 Figure 79: Europe Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 80: Europe Market Attractiveness by Country, 2022 to 2032 Figure 81: East Asia Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 82: East Asia Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 83: East Asia Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 84: East Asia Market Value (US$ Million) by Country, 2022 to 2032 Figure 85: East Asia Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 88: East Asia Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 89: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 91: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 92: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 94: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 95: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 97: East Asia Market Attractiveness by Drug Type, 2022 to 2032 Figure 98: East Asia Market Attractiveness by Route of Administration, 2022 to 2032 Figure 99: East Asia Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 100: East Asia Market Attractiveness by Country, 2022 to 2032 Figure 101: South Asia & Pacific Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 102: South Asia & Pacific Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 103: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 104: South Asia & Pacific Market Value (US$ Million) by Country, 2022 to 2032 Figure 105: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 106: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 107: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 108: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 109: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 110: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 111: South Asia & Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 112: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 113: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 114: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 115: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 116: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 117: South Asia & Pacific Market Attractiveness by Drug Type, 2022 to 2032 Figure 118: South Asia & Pacific Market Attractiveness by Route of Administration, 2022 to 2032 Figure 119: South Asia & Pacific Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 120: South Asia & Pacific Market Attractiveness by Country, 2022 to 2032 Figure 121: MEA Market Value (US$ Million) by Drug Type, 2022 to 2032 Figure 122: MEA Market Value (US$ Million) by Route of Administration, 2022 to 2032 Figure 123: MEA Market Value (US$ Million) by Distribution Channel, 2022 to 2032 Figure 124: MEA Market Value (US$ Million) by Country, 2022 to 2032 Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 128: MEA Market Value (US$ Million) Analysis by Drug Type, 2017 to 2032 Figure 129: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2022 to 2032 Figure 130: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2022 to 2032 Figure 131: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032 Figure 132: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032 Figure 133: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032 Figure 134: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032 Figure 135: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032 Figure 136: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032 Figure 137: MEA Market Attractiveness by Drug Type, 2022 to 2032 Figure 138: MEA Market Attractiveness by Route of Administration, 2022 to 2032 Figure 139: MEA Market Attractiveness by Distribution Channel, 2022 to 2032 Figure 140: MEA Market Attractiveness by Country, 2022 to 2032
Explore Healthcare Insights
View Reports